The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 7332170 B1

PDF
Full Text
Expired
Date of Patent:
Feb. 19, 2008

Filed:

Dec. 23, 2005
Applicants:

Manuel V. Borca, Westbrook, CT (US);

Guillermo R. Risatti, Westbrook, CT (US);

Daniel L. Rock, Monticello, IL (US);

Inventors:

Manuel V. Borca, Westbrook, CT (US);

Guillermo R. Risatti, Westbrook, CT (US);

Daniel L. Rock, Monticello, IL (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 39/00 (2006.01); C12N 15/09 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
Abstract

Transposon linker insertion mutagenesis of a full-length infectious clone of the highly pathogenic classical swine fever virus (CSFV) isolate Brescia (pBIC) was used to identify genetic determinants of CSFV virulence and host range. A virus mutant, RB-C22 (RB-C22v), possessing a 19-residue tag insertion at the carboxyl end of E1 was constructed. RB-C22v and the parental virus pBIC (pBICv) exhibited similar growth characteristics on primary porcine macrophage cell cultures although RB-C22v produced significantly smaller plaques on SK6 cell cultures. In vivo, RB-C22v was markedly attenuated in swine. In contrast with pBIC infection, where mortality was 100%, all RB-C22v-infected pigs survived infection remaining clinically normal. Additionally, chimeras of the Brescia strain and the attenuated vaccine strain CS were constructed and evaluated for viral virulence in swine. Chimeras 138.8v and 337.14v, chimeras containing the E2 glycoprotein of CS and chimeric virus 319.1v, which contained only the CS E2 glycoprotein in the Brescia background, were attenuated in swine. Chimeras encoding all Brescia structural proteins in a CS genetic background remained attenuated, indicating that additional mutations outside the structural region are important for CS vaccine virus attenuation. The combined results indicate a significant role for E1 glycoprotein and E2 glycoprotein in swine virulence.


Find Patent Forward Citations

Borca, Manuel. (2008). Classical swine fever virus virulence determinant and a novel classical swine fever vaccine (U.S. Patent No. 7332170). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/7332170

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…